EverHint Lens - CytomX Therapeutics, Inc. (CTMX) - Top Gainer (+71%) Stock Analysis - March 16, 2026
Analysis Date: 2026-03-16
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Executive Summary
CytomX Therapeutics, Inc. is currently trading at $8.01 (🟢 +71.15% today) with a market capitalization of $1.36B.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer.
Price & Valuation
Current Price: $8.01 (at 1:32 PM ET)
Current Volume: 98.0M
Day Range: $6.04 - $8.20
52-Week Range: $0.40 - $8.20
P/E Ratio: 47.17
DCF Valuation: Not applicable (negative intrinsic value)
DCF model (unlevered) calculated as of 2026-03-16.
Market Context
Healthcare Sector: 0.33287% | Sector P/E: 26.28
Major Indices:
- S&P 500: $6702.73 (🟢 +1.06%)
- NASDAQ Composite: $22401.49 (🟢 +1.34%)
- Dow Jones Industrial Average: $46950.12 (🟢 +0.84%)
Peer Comparison
Peer comparison (11 companies):
- CTMX - CytomX Therapeutics, Inc. ($8.01, +71.2%, $1.36B) ← Current
- ERAS - Erasca, Inc. ($13.97, +2.6%, $4.32B)
- IOVA - Iovance Biotherapeutics, Inc. ($3.96, +0.1%, $1.31B)
- MLTX - MoonLake Immunotherapeutics ($16.95, -1.1%, $1.22B)
- AVBP - ArriVent BioPharma, Inc. Common Stock ($24.47, +2.4%, $1.08B)
- MBX - MBX Biosciences, Inc. Common Stock ($30.21, +7.9%, $1.01B)
- ATXS - Astria Therapeutics, Inc. ($12.58, 0.0%, $718M)
- MGTX - MeiraGTx Holdings plc ($7.63, +3.2%, $614M)
- REPL - Replimune Group, Inc. ($7.35, +2.9%, $607M)
- AVXL - Anavex Life Sciences Corp. ($4.76, +2.4%, $441M)
- DNA - Ginkgo Bioworks Holdings, Inc. ($6.74, -1.0%, $417M)
Financial Performance
Latest Quarter (2025-09-30):
- Revenue: $5.96M
- Net Income: $-14.23M
- EPS: $-0.09
- Revenue Growth (QoQ): -68.0%
Earnings Calendar
Next Earnings Report: 2026-04-30 (During Trading Day)
- EPS Estimate: $-0.10
- Revenue Estimate: $0.01B
Most Recent Report: 2026-03-16
- EPS: $-0.33 (Est: $-0.09) ✗ Miss
- Revenue: $0.00B
Historical Data: 49 earnings events tracked
Analyst Outlook
Analyst Price Target Consensus:
- Target: $10.50 (+31.1% upside)
- Range: $10.00 - $12.00
- Median: $10.00
Next Quarter Estimates (2026-12-30):
- Revenue: $5.63M
- EPS: $-0.11
Analyst Consensus
Overall Rating: Buy
Rating Distribution (107 total ratings):
- 🟢 Buy/Outperform: 67 (62.6%)
- ⚪ Hold/Neutral: 34 (31.8%)
- 🔴 Sell/Underperform: 4 (3.7%)
Recent Analyst Actions:
- JP Morgan (2026-03-16): Neutral → Overweight
- HC Wainwright & Co. (2026-03-16): Maintained Buy
- Guggenheim (2026-03-09): Maintained Buy
- Cantor Fitzgerald (2026-02-04): Maintained Overweight
- Barclays (2026-02-04): Maintained Overweight
Consensus based on 107 analyst ratings from major financial institutions
Insider Activity
Recent Transactions (Last 10):
- Buys: 10
- Sells: 0
Notable Transactions:
- 2026-02-02: Lester Rachael - Buy (Award, 50,000 shares)
- 2026-02-02: Lester Rachael - Buy (Award, 50,000 shares @ $6.09)
- 2026-02-02: Lester Rachael - Buy (Award, 20,000 shares)
News Sentiment Analysis
AI Analysis (based on 30 recent articles):
Recent headlines emphasize positive Phase 1 data for Varseta-M in colorectal cancer, with strong response rates and progression-free survival, fueling a stock rally and 'Moderate Buy' consensus from analysts. Despite Q3 and Q4 2025 earnings misses, the focus is on pipeline progress, upcoming catalysts, and biomarker data. Overall sentiment is optimistic about CytomX's clinical advancements.
Key Themes:
- Positive Clinical Trial Results
- Analyst Buy Ratings and Stock Rally
- Upcoming Milestones and Pipeline Updates
Sentiment: Positive (92% confidence)
Reddit Sentiment
Community Discussion (last 30 days from r/wallstreetbets, r/stocks, r/investing):
Overall Sentiment: Strongly Bullish 📈📈 (Score: 0.840)
Post Analysis:
- Total posts: 3
- Bullish: 3 (100.0%)
- Bearish: 0 (0.0%)
- Neutral: 0 (0.0%)
- Total engagement: 56 (upvotes + comments)
Note: Sentiment score ranges from -1.0 (very bearish) to +1.0 (very bullish), weighted by post engagement.
Recent News
5 most recent articles covering CTMX:
- Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally (benzinga.com, 2026-03-16) — Read more
- CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript (seekingalpha.com, 2026-03-16) — Read more
- CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates (zacks.com, 2026-03-16) — Read more
- CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update (globenewswire.com, 2026-03-16) — Read more
- CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer (globenewswire.com, 2026-03-16) — Read more
Full news analysis based on 30 recent articles
Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-03-16 10:33:05 AM PDT
Disclaimer: This is not investment advice. Always do your own research before making investment decisions.